This document presents a discussion of the characteristics for consideration during the validation of the analytical procedures included as part of registration applications submitted within the EC, Japan and USA. This document does not necessarily seek to cover the testing that may be required for registration in, or export to, other areas of the world. Furthermore,this text presentation serves as a collection of terms, and their definitions, and is not intended to provide  the differences that often exist between various compendia and regulators of the EC,Japan and USA.
The objective of validation of an analytical procedure is to demonstrate that it is suitable for its intended purpose. A tabular summation of the characteristics applicable to identification,control of impurities and assay procedures is included. Other analytical procedures may be considered in future additions to this document.

The discussion of the validation of analytical procedures is directed to the four most common
types of analytical procedures:
• Identification tests.
• Quantitative tests for impurities’ content.
• Limit tests for the control of impurities.
• Quantitative tests of the active moiety in samples of drug substance or drug product or
other selected component(s) in the drug product.
Although there are many other analytical procedures, such as dissolution testing for drug products or particle size determination for drug substance, these have not been addressed in the initial text on validation of analytical procedures. Validation of these additional analytical procedures is equally important to those listed herein and may be addressed in subsequent documents.
A brief description of the types of tests considered in this document is provided below.
• Identification tests are intended to ensure the identity of an analyte in a sample. This is normally achieved by comparison of a property of the sample (e.g., spectrum,chromatographic behavior, chemical reactivity, etc) to that of a reference standard.
• Testing for impurities can be either a quantitative test or a limit test for the impurity in a sample. Either test is intended to accurately reflect the purity characteristics of the sample. Different validation characteristics are required for a quantitative test than for a limit test.
• Assay procedures are intended to measure the analyte present in a given sample. In the context of this document, the assay represents a quantitative measurement of the major component(s) in the drug substance. For the drug product, similar validation characteristics also apply when assaying for the active or other selected component(s).

The same validation characteristics may also apply to assays associated with other analytical procedures (e.g., dissolution).
The objective of the analytical procedure should be clearly understood since this will govern the validation characteristics which need to be evaluated. Typical validation characteristics which should be considered are listed below:
Intermediate Precision
Detection Limit
Quantitation Limit
Each of these validation characteristics is defined in the attached Glossary. The table lists those validation characteristics regarded as the most important for the validation of different types of analytical procedures. This list should be considered typical for the analytical procedures cited but occasional exceptions should be dealt with on a case-by-case basis. It should be noted that robustness is not listed in the table but should be considered at an appropriate stage in the development of the analytical procedure.
Furthermore revalidation may be necessary in the following circumstances:
• changes in the synthesis of the drug substance;
• changes in the composition of the finished product;
• changes in the analytical procedure;
The degree of revalidation required depends on the nature of the changes. Certain other changes may require validation as well.

AAA 2 -



– signifies that this characteristic is not normally evaluated
+ signifies that this characteristic is normally evaluated
(1) in cases where reproducibility (see glossary) has been performed, intermediate precision
is not needed
(2) lack of specificity of one analytical procedure could be compensated by other
supporting analytical procedure(s)
(3) may be needed in some cases

For More Pharma Updates Visit –

Reference: ICH Topic Q 2 (R1) Validation of Analytical Procedures:Text and Methodology

About Pharmaceutical Guidanace

Mr. Shiv Kumar is the Author and founder of pharmaceutical guidance, he is a pharmaceutical Professional from India having more than 14 years of rich experience in pharmaceutical field. During his career, he work in quality assurance department with multinational company’s i.e Zydus Cadila Ltd, Unichem Laboratories Ltd, Indoco remedies Ltd, Panacea Biotec Ltd, Nectar life Science Ltd. During his experience, he face may regulatory Audit i.e. USFDA, MHRA, ANVISA, MCC, TGA, EU –GMP, WHO –Geneva, ISO 9001-2008 and many ROW Regularities Audit i.e.Uganda,Kenya, Tanzania, Zimbabwe. He is currently leading a regulatory pharmaceutical company as a head Quality. You can join him by Email, Facebook, Google+, Twitter and YouTube

Check Also

A 9 -

Production and Process Controls in Pharma industry as per USFDA

Production and Process Controls in Pharma industry as per USFDA Written procedures; deviations (21 CFR …

error: Content is protected !!